Certain subgroups of patients with hematologic malignancies are more prone to experience distress and depression, researchers concluded after conducting a study involving 246 individuals. Participants with hematologic malignancies completed the Patient Health Questionnaire 9 (PHQ-9) and Distress Thermometer (DT) prior to receiving outpatient parenteral chemotherapy. Among the results:
- PHQ-9 score of ≥ 9 and DT score ≥ 4 pointed to a high risk of major depression and distress.
- PHQ-9 score ≥ 9 was linked with living alone, positive PHQ-2, and high Charlson comorbidity index.
- DT score ≥4 was linked with being married and female.
The authors noted that at-risk subgroups should be aggressively screened even in the absence of universal screening programs.
Shreders A, Niazi S. Hodge D, et al. Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. [Published online ahead of print December 7, 2017]. Ann Hematol. doi:10.1007/s00277-017-3198-0.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al